Navigation Links
Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), will present results of its ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16 at the American Association for Cancer Research - Molecular Targets and Cancer Therapeutics Conference in Boston. Apoptone, a novel steroid that is an analog of part of the dihydrotestosterone metabolic pathway, stimulates ERK1 signal transduction that counter-regulates PI3K, and thereby initiating tumor cell apoptosis. Apoptone has demonstrated activity in animal models of CRPC, the results of which were recently published in the British Journal of Cancer and the journal Neoplasia.

Concurrently with its lead program Apoptone, Hollis-Eden Pharmaceuticals is pursuing clinical development of a second oral small-molecule candidate, Triolex®, from its synthetic steroid library. Triolex decreases macrophage infiltration into fatty tissues and pro-inflammatory processes. The lead indication for Triolex is Type 2 diabetes. A Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients is fully enrolled and should be completed in the first quarter of 2010. A Phase I trial (HE3286-0102) to assess safety and early activity in obese insulin-resistant, pre-diabetic subjects is complete, with final analysis in progress. Additional trials were initiated during 2008 in rheumatoid arthritis (RA) and ulcerative colitis (UC).

James Frincke, Ph.D., Chief Executive Officer of Hollis-Eden Pharmaceuticals commented: "We have reduced our burn rate to enable operations focused on our lead programs to continue into the latter half of 2010. We intend to use data from our ongoing trials to eng
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
2. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
3. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Viron to Present Data from Phase II Trial at American Heart Association Conference
7. Curemark Presents at Springboard Enterprises Life Sciences Forum
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
9. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
10. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 Research ... the "Animal Genetics Market by Products, by Testing ... their offering. The global animal genetics market ... 2014 and grow at a CAGR of 8-9% during ... This market is mainly driven by increasing animal protein ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... cooperative research center program (I/UCRC) will "provide a one-stop ... wide range of metamaterials." Dr. David Crouse, associate ... Engineering at The City College of New York, serves ... Participating institutions are The City University of ...
... Inc. (OTCBB: PEDX) announced that the U.S. Centers ... state Medicaid agencies to include PediatRx,s GRANISOL, NDC ... funds the Medicaid and State Children Health Insurance ... health insurance, including prescription drug coverage, to over ...
... 2011 Cellular Dynamics International (CDI), the ... induced pluripotent stem cell (iPSC) lines, today announced it ... patented definitive endoderm differentiation technology from ViaCyte, Inc. ... CDI will apply this patented methodology in the development ...
Cached Biology Technology:Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 2GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 3GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 4Cellular Dynamics Licenses Technology From ViaCyte 2Cellular Dynamics Licenses Technology From ViaCyte 3
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... in the Proceedings of the National Academy of Sciences ... from the Kennedy Krieger Institute and four collaborating institutions, identified ... to the development of glaucoma and its resulting vision loss. ... head, the point where the cables that carry information from ...
... researchers led by Daniel J. Rader, MD, associate ... and Therapeutics, has received a $6 million grant ... molecular genetics of atherosclerotic cardiovascular disease. The team,s ... Plasma Lipids and Cardiovascular Disease," was selected to ...
... vomiting hairballs or refusing to eat probably isn,t being finicky ... is a good chance that the cat is acting sick ... new research suggests. Healthy cats were just as likely ... leave waste outside their litter box in response to changes ...
Cached Biology News:New research reveals unexpected biological pathway in glaucoma 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Even healthy cats act sick when their routine is disrupted 2Even healthy cats act sick when their routine is disrupted 3Even healthy cats act sick when their routine is disrupted 4Even healthy cats act sick when their routine is disrupted 5
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... top-of-the-line PowerPac 3000 power supply is ... ideal for isoelectric focusing, DNA sequencing, ... electrophoresis, western blotting, and submerged gel ... of powre, the PowerPac 3000 power ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The wide mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
Biology Products: